Innovative Medicines Canada applauds Quebec’s new Life Sciences Strategy
Ottawa, May 12, 2022 – Innovative Medicines Canada (IMC), the association representing Canada’s research-based pharmaceutical sector, welcomes Quebec’s new Life Sciences Strategy. This strategy is a critical step towards improving Quebec’s research and development (R&D) competitiveness, clinical pharmaceutical research and biomanufacturing that will have a positive impact on Quebec’s socio-economic development.
“We congratulate the Quebec government on working with our sector to develop a strategy that focuses on attracting biopharmaceutical investments and applying lessons from the pandemic to enhance the health of Quebec residents and its economy,” said Pamela Fralick, President of Innovative Medicines Canada.
IMC is pleased the Strategy focuses on collaboration between key stakeholders, including the federal government, to ensure ongoing dialogue and that it includes recommendations to encourage timely access to new treatments for patients in Quebec.
The research-based pharmaceutical industry contributes $5.1 billion per year to the Quebec economy and generates 38,000 high-quality jobs in the province. Forty-two per cent of IMC members’ headquarters are in Quebec, in addition to nearly 50 per of the industry’s research & development jobs in Canada.
About Innovative Medicines Canada
Innovative Medicines Canada is the national association representing the voice of Canada’s innovative pharmaceutical industry. The association advocates for policies that enable the discovery, development, and delivery of innovative medicines and vaccines to improve the lives of all Canadians and supports the members’ commitment to being a valued partner in the Canadian healthcare system. The association represents 49 companies who invest nearly $1.2 billion in R&D annually, fueling Canada’s knowledge-based economy, while contributing $8 billion to Canada’s economy. Guided by the Code of Ethical Practices, all members work with governments, private payers, healthcare professionals, and stakeholders in a highly ethical manner.
– 30 –
For further information:
Director, Media Relations & Content